PCM
NWBO

Price Capital Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Price Capital Management’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-28,864
Closed -$213K – 301
2015
Q1 		$213K Buy
+28,864
New +$194K 0.13% 293

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CWM
CIBC World Markets New York $20.8B AUM

Price Capital Management's NWBO Position: Q2 2015 in Review

Price Capital Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2015, closing a stake of 28,864 shares — an estimated $213K sold.

Price Capital Management first reported a position in NWBO in Q1 2015 and held it in 1 quarter. The position peaked at $213K in Q1 2015. 83 funds tracked by Wall St. Rank hold NWBO as of Q2 2015.

  • Price Capital Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2015 after selling out during the quarter.
  • Price Capital Management sold 28,864 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2015, an estimated $213K.
  • Price Capital Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2015 and held it in 1 quarter.
  • Price Capital Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $213K in Q1 2015.
  • 83 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2015.

Based on Price Capital Management's 13F filing for Q2 2015.